Neurizon Therapeutics Target Price for 2026

Neurizon Therapeutic...

ASX:NUZ

$ 0,08

$-0,01 (-11,11%)

0,08 $

$-0,01 (-11,11%)

End-of-day quote: 04/08/2026

Neurizon Therapeutics Stock Value

According to analysts, the current valuation of ASX:NUZ is Buy.

Buy

Neurizon Therapeutics Company Info

EPS Growth 5Y

0,00%

Market Cap

$0,06 B

Long-Term Debt

$0,00 B

Quarterly earnings

N/A

Dividend

$0,00

Dividend Yield

0,00%

Founded

2000

Industry

Health Care

Country

Australia

Website

Neurizon Therapeutics

ISIN Number

AU0000357261

Website

http://www.pharmaust.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$0,28

250%

Last Update: 04/07/2026

Analysts: 1

Highest Price Target $0,28

Average Price Target $0,28

Lowest Price Target $0,28

In the last five quarters, Neurizon Therapeutics’s Price Target has risen from $0,00 to $0,08 - a 100,00% increase.

Top growth stocks in the health care sector (5Y.)

What does Neurizon Therapeutics do?

Neurizon Therapeutics Limited a clinical stage biotechnology company that develops therapeutics for neurodegenerative diseases. Business Segments The company operates through Pharmaceuticals – Epichem segment. The Epichem segment is dedicated to the pharmaceutical development side, offering advanced chemical development services. This is specifically tailored to assist clients in the pharmaceutical industry, providing expertise and resources to facilitate the drug development process from prec...

Neurizon Therapeutics Limited a clinical stage biotechnology company that develops therapeutics for neurodegenerative diseases.

Business Segments

The company operates through Pharmaceuticals – Epichem segment. The Epichem segment is dedicated to the pharmaceutical development side, offering advanced chemical development services. This is specifically tailored to assist clients in the pharmaceutical industry, providing expertise and resources to facilitate the drug development process from preclinical to clinical phases.

Business Strategy

The company’s business strategy is primarily oriented towards enhancing its drug development pipeline while also providing critical support services through Epichem. The company seeks to cultivate partnerships with other biotech firms and pharmaceutical companies to co-develop products, leveraging shared expertise and resources. This collaboration is essential for navigating regulatory landscapes, optimizing research outcomes, and securing funding for clinical trials.

In addition, the company is committed to upholding strong research ethics and maintaining a compliance-focused approach to ensure that all developments adhere to the highest standards of safety and efficacy. The company is strategizing on employing breakthrough technologies to handle innovations rapidly, targeting increased efficiencies in its research and manufacturing processes. By investing in cutting-edge research facilities and state-of-the-art technology, the company aims to position itself as a leader in drug discovery not only in veterinary applications but also expanding into human healthcare.

Furthermore, the company hopes to enhance its market presence through systematic brand positioning, consistent engagement with stakeholders, and active participation in industry conferences. The focus on securing intellectual property rights is another pillar of its strategy, establishing a robust foundation for future revenue generation.

Products and Services

The company offers a variety of products and services designed to cater to both veterinary and human health markets. The key offerings include:

Oncology Therapeutics: The flagship products under development target various forms of cancer, with a strong emphasis on innovative treatments that leverage the company’s proprietary technologies.

Epichem Services: As part of the pharmaceutical development segment, Epichem provides specialized chemical synthesis and process development services. This includes the provision of high-quality reagents necessary for drug formulation, thereby supporting clients in their development pipelines.

Research Capabilities: The company boasts extensive research capabilities in drug discovery, focusing on oncology and other therapeutic areas. This segment is responsible for the identification and validation of new drug candidates, as well as conducting preclinical and clinical studies.

Regulatory Support: The company offers regulatory consultancy services to its clients, ensuring that their products meet necessary compliance standards throughout development stages.

Geographical Markets

The company operates primarily within the Australian market. However, it has established a presence in international markets, most notably in Switzerland and the United States.

Customers

The company serves a diverse array of customers, primarily within the biotech and pharmaceutical sectors. Major customers include veterinary clinics, pharmaceutical companies, and research institutions that seek innovative therapies and development services.

Marketing

The company employs a multi-faceted marketing and distribution strategy, targeting both direct and indirect channels to reach its diverse customer base. The marketing efforts are directed towards establishing the company as a thought leader in the biotech sector and engaging with stakeholders through industry events, publications, and targeted communications. Direct marketing channels include providing consultancy services in drug development and promoting its proprietary therapeutics via collaborations with other pharmaceutical companies.

History

The company was incorporated in 2000. It was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.

New support ticket

Explore

Neurizon Therapeutics Stock Value

Neurizon Therapeutics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Neurizon Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Neurizon Therapeutics Stock Value

Neurizon Therapeutics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Neurizon Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.